幹細胞研究と治療のジャーナル

概要

Allogeneic Mesenchymal Stem Cells Infusion to an ALS Patient Proved to be Safe and Capable to Initiate Clinical Recuperation: Review

J.J. Minguell , C. Allers , J. A. Jones , S.S. Ganji

No cure has been found for Amyotrophic Lateral Sclerosis (ALS) despite several studies using drugs or related compounds. Background: Cellular, molecular and preclinical studies have suggested that the use of Mesenchymal Stem Cells (MSC) may represent a therapeutic option for ALS treatment. MSC exhibit a capability for self-renewal, differentiation (mesoderm and neuroectoderm phenotypes) and production/release of neuroprotective mediators. All these attributes epitomize an option for using MSC in ALS. Materials and Methods: Minimally manipulated ex vivo expanded allogeneic bone marrow-derived MSC (0.6 x 106 MSC/kg body weight) were intrathecally infused to an ALS patient. Quantitative clinical assessments as well as vital signs, access site and neurological clinical assessment were monitored after cell infusion.